ClinicalTrials.Veeva

Menu

Consequences of a Maternal-fetal Chikungunya Virus Infection (CHIK13+)

C

Centre Hospitalier Universitaire de la Réunion

Status

Completed

Conditions

Chikungunya Virus Infection

Treatments

Other: NEUROPSYCHOLOGICAL ASSESSMENT
Other: OPHTHALMOLOGICAL ASSESSMENT

Study type

Interventional

Funder types

Other

Identifiers

NCT04909411
2018/CHU/07

Details and patient eligibility

About

Chikungunya is an infectious disease caused by an alphavirus transmitted by the Aedes mosquitoes which has known a worldwide expansion since its re-emergence in 2004. Regarding to an unprecedented epidemic, Reunionese pediatricians described in 2005-2006 a vertical maternal-fetal transmission of this virus, at the time of childbirth. Since then, this mode of transmission has been widely confirmed, with an absolute risk estimated between 15.5% and 48.3%. The main consequences for the child are neuromotor, neurosensory or neurocognitive. They were studied around the age of 2 in 33 children in the CHIMERE cohort, as well as at the age of 5 in a small fraction of these children followed at the C.A.M.S.P (Center for Early Medico-Social Action). The results suggested an overall delay in psychomotor acquisitions secondary to neonatal infection, affecting the functions of the prefrontal region (in particular coordination and language). Performance was correlated with the severity of the clinical presentation (more severe in case of encephalitis or encephalopathy) while remaining suboptimal in children with uncomplicated infection. During neurodevelopmental monitoring, other disturbing traits complemented the spectrum of problems presented by these children, such as microcephaly, cerebral palsy, epilepsy, interaction disorder or attention deficit disorder. At around age 10, the investigators reassessed 21 of these children using the Childhood Cognitive Function and Learning (EDA) screening test. The investigators would now like to confirm and characterize their impairments using a battery of confirmatory tests around the age of 13.

Enrollment

42 patients

Sex

All

Ages

10 to 16 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Child born between March 2005 and July 2006
  • Of which the mother identified in the CHIMERE cohort or the perinatal register of maternities
  • Exposed: child infected with the chikungunya virus at the time of childbirth
  • Not exposed: child not infected with the chikungunya virus at the time of childbirth, verifying the matching criteria specified in chapter 5.2
  • Affiliated to a social insurance

Exclusion criteria

  • Prematurity <33 weeks
  • Prenatal alcoholization authenticated by fetal alcohol syndrome
  • Intellectual disability or secondary epilepsy of origin other than CHIKV infection (caused by ACSOS or any other cause of brain damage of inflammatory, metabolic or infectious origin)

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

42 participants in 2 patient groups

Exposed arm
Other group
Description:
child infected with chikungunya virus during childbirth
Treatment:
Other: OPHTHALMOLOGICAL ASSESSMENT
Other: NEUROPSYCHOLOGICAL ASSESSMENT
Non-exposed arm
Other group
Description:
child not infected with the chikungunya virus at the time of childbirth, verifying the matching criteria specified
Treatment:
Other: OPHTHALMOLOGICAL ASSESSMENT
Other: NEUROPSYCHOLOGICAL ASSESSMENT

Trial contacts and locations

1

Loading...

Central trial contact

Samir MEDJANE, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems